In a remote trial reported in eClinicalMedicine, a smartphone app called START has shown that it can help a group of men long underserved by HIV care keep the virus in check. Among 286 sexual minority men in the continental United States who use stimulants, those given the app were less likely to have detectable viral load at six months than those referred only to a website of care resources. The finding matters because the path from diagnosis to suppression is most fragile for people whose lives are shaped by stimulant use, and the app works by catching the slide back toward detectable virus
Mobile App Lowers Detectable HIV Viral Load Among Sexual Minority Men Using Stimulants
Prevented virologic rebound in people at high risk of disengaging
Mark
So what did this trial actually find?
Mimi
That men with HIV who use stimulants and were given the START app had lower odds of a detectable viral load at six months than men given a website of referrals.
Mark
Why does the control matter?
Mimi
It isn't a do-nothing group. Everyone got something, so the app is being compared with a basic resource list.
Luke
Fair, but the reporting gives us the direction, not the size. We're told the odds were significantly lower, with no figures for how much.
Mark
What about the idea that it prevents rebound?
Mimi
That's the researchers' interpretation. It matters because people at high risk of dropping out of care tend to lose suppression, so holding it is the goal.
Luke
I'd keep that as an interpretation. The summary doesn't tell us how many people rebounded in each arm.
Mark
And the fact that it works regardless of readiness to cut back on stimulants?
Mimi
That's the design, and it lowers the bar for who can use it. Many programmes expect people to want to quit first.
Luke
Design intent isn't proof it worked for people at every stage of readiness. We don't have that breakdown.
Mark
What's still unknown?
Luke
Whether the effect lasts past six months, though 12-month samples were collected, and whether it applies beyond this group.
Der Puls
- A remote trial of 286 men who use stimulants tested whether a phone app could keep their HIV under control.
- Detectable virus is the danger signal, and the study measured it at six months against a website-referral control.
- The app appears to stop virologic rebound, the quiet slide back to detectable virus that undoes treatment.
- The gains are promising, yet the 12-month picture and other stimulant-using groups are still unresolved.
In a remote trial reported in eClinicalMedicine, a smartphone app called START has shown that it can help a group of men long underserved by HIV care keep the virus in check. Among 286 sexual minority men in the continental United States who use stimulants, those given the app were less likely to have detectable viral load at six months than those referred only to a website of care resources. The finding matters because the path from diagnosis to suppression is most fragile for people whose lives are shaped by stimulant use, and the app works by catching the slide back toward detectable virus before it takes hold. Whether that protection endures beyond the early window remains the question that will shape its place in the wider story of HIV prevention.
A randomised trial published in eClinicalMedicine suggests that a smartphone app can lower the odds of detectable HIV viral load among sexual minority men who use stimulants. The study ran remotely and enrolled 286 participants across the continental United States, all of whom had screened positive for a stimulant use disorder.
The app, called Supporting Treatment Adherence for Resilience and Thriving, or START, is designed to help people stay on antiretroviral therapy. Participants were randomly assigned either to START or to a control website offering referrals to care resources. The primary outcome was viral load above 300 copies per millilitre, measured from blood samples collected remotely at baseline, six months and 12 months. At six months, people using the app were significantly less likely to have detectable virus than those given the website.
The researchers believe the app works mainly by preventing virologic rebound, the return of detectable virus after it has been controlled. That matters because people at high risk of leaving treatment depend on avoiding exactly that slide. START also draws on positive psychological skills and aims to improve adherence whether or not a participant is ready to reduce stimulant use, removing a condition many programmes quietly impose.
The population at stake is substantial. Stimulants, methamphetamine especially, drive much of the HIV epidemic, and as many as one in three sexual minority men who acquire HIV in the United States report persistent use. The open question is durability: whether the benefit holds beyond six months and extends to other stimulant-using groups will determine the app's wider value to public health.
A randomised trial published in eClinicalMedicine reports that a smartphone app lowered the odds of detectable HIV viral load, at six months, among sexual minority men with HIV who also use stimulants. The trial was run remotely, and it enrolled 286 participants from across the continental United States.
The app is called Supporting Treatment Adherence for Resilience and Thriving, or START. It is built to help people stay on antiretroviral therapy. Participants were randomised to receive either START or a control: a website that offered referrals to care resources. All of them had screened positive for a stimulant use disorder.
The primary outcome was detectable viral load, defined as more than 300 copies per millilitre. Blood samples were collected remotely at baseline, at six months and at 12 months. The headline result is the six-month one: the odds of a detectable viral load were significantly lower among people using the app than among those given the website.
The researchers' reading is that the app worked mainly by preventing virologic rebound, meaning a return of detectable virus after it had been controlled. That matters for people at high risk of disengaging from treatment, since keeping viral suppression in place depends on avoiding exactly that kind of slide.
The study speaks to a gap in the evidence on digital health. Earlier work has tended to show moderate gains in self-reported adherence but inconsistent effects on objective biomarkers such as viral load. Randomised trials in lower- and middle-income countries have shown that two-way text messaging can reduce detectable viral load. For key populations facing outsized difficulties, including sexual minority men who use stimulants, the evidence has been thin.
The population is not a small one. Methamphetamine and other stimulants are a prominent driver of the HIV epidemic, and as many as one in three sexual minority men who acquire HIV in the United States report persistent methamphetamine use. These men often have a harder time with adherence, which raises the likelihood of detectable viral load and, with it, the risk of onward transmission.
The design of START responds to that. The app integrates skills from positive psychological intervention, and it is meant to improve adherence whether or not a participant is ready to cut back on stimulant use. That removes a condition that many programmes quietly impose.
The open question is durability. The reported benefit is at six months, and blood was also drawn at 12 months. Whether the gains hold beyond the early window, and whether they carry over to other stimulant-using groups, will decide how much the app can contribute to public health more broadly.
Bemerkenswerte Zitate
The app significantly lowered the odds of detectable HIV-1 viral load at six months, mainly by preventing virologic rebound.— Trial findings published in eClinicalMedicine (paraphrased)
Möchten Sie die ganze Geschichte?
Das Original lesen bei European AIDS Treatment Group ↗
Health & Medicine